Over $600 billion in European goods were imported by the U.S. last year. New tariffs from President Trump will likely hit ...

Market report delivers crucial insights into the market's growth trajectory and the primary revenue drivers anticipated ...

Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of 2024 while its obesity treatment counterpart Zepbound brought in $1.9 ...

This surge was largely driven by its blockbuster GLP-1 receptor agonists, Mounjaro and Zepbound, which dominate the obesity and diabetes markets. Eli Lilly’s net income doubled compared to Q4 ...

The deal establishes Lilly with a diverse pipeline to target the large market opportunity within MASH. The drugmaker’s blockbuster GLP-1RA drug tirzepatide – the active ingredient in Mounjaro ...

Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big Pharma is coughing up cash to work with them on radiopharmaceuticals ...

This surge was largely driven by its blockbuster GLP-1 receptor agonists, Mounjaro and Zepbound, which dominate the obesity and diabetes markets. Eli Lilly’s net income doubled compared to Q4 2023, ...

Private health insurers say they will not cover the cost of Mounjaro, a medicine from Eli Lilly which has been approved for the treatment of obesity and diabetes in the Irish market. The drug is ...

Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology. After a thorough review ...

Eli Lilly should continue to grow its top line faster than its similarly sized peers. Its lineup features several blockbusters, including its popular diabetes and weight loss medicines ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... driven by strong volume growth from Mounjaro and Zepbound. Earnings per share (EPS) for the quarter doubled ...